---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-128825"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-11-17T12:14:19+00:00"
generated_at: "2026-11-17T12:15:06.411420+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# SELLAS GPS hits Phase 3 REGAL primary endpoint: median OS 24.0 vs 14.7 months, HR 0.59 (p=0.035)

## Summary
- Median overall survival 24.0 months for galinpepimut-S (GPS) vs 14.7 months for best available treatment; 41% reduction in risk of death (HR 0.59, two-sided p=0.035).
- REGAL enrolled AML patients in second or later complete remission (CR2/CRp2+) after second-line or later salvage therapy who were ineligible for allogeneic stem cell transplant.
- Topline analysis conducted at the pre-specified 80 death events per the trial's statistical analysis plan; treatment arms balanced on prognostic factors.
- GPS generally well tolerated; treatment-related adverse events mostly grade 1/2 local injection site reactions, no new safety signals.
- SELLAS plans an FDA meeting on an accelerated filing strategy and to advance BLA preparation for GPS in the first half of 2027; secondary endpoints pending.

## SEC filing metadata
- accession: 0001104659-26-128825
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-11-17T12:14:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/0001104659-26-128825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/tm2629947d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-128825
- JSON: https://secwatch.observer/filing/0001104659-26-128825.json
- Plain text: https://secwatch.observer/filing/0001104659-26-128825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
